Analyst Activity – Goldman Sachs Group Inc Lowers Its Price Target On Amgen (NASDAQ:AMGN) to

12

Analyst Ratings For Amgen (NASDAQ:AMGN)

Today, Goldman Sachs Group Inc lowered its price target on Amgen (NASDAQ:AMGN) to per share.

There are 9 hold ratings, 12 buy ratings on the stock.

The current consensus rating on Amgen (NASDAQ:AMGN) is Buy (Score: 2.57) with a consensus target price of $187.89 per share, a potential 11.43% upside.

Some recent analyst ratings include

  • 3/17/2017-Robert W. Baird Reiterated Rating of Neutral.
  • 3/17/2017-Cowen and Company Reiterated Rating of Buy.
  • 3/15/2017-Cann Reiterated Rating of Outperform .
  • 3/14/2017-Oppenheimer Holdings Inc. Reiterated Rating of Outperform.
  • 3/14/2017-Piper Jaffray Companies Reiterated Rating of Overweight.

Dividend information for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) pays an annual dividend of $4.60 with a yield of 2.73% and an average dividend growth of 28.60% based on a 3 Year Average..

Dividend History for Amgen (NASDAQ:AMGN)

  • On 3/7/2017 Amgen announced a quarterly dividend of $1.15 2.59% with an ex dividend date of 5/15/2017 which will be payable on 6/8/2017.
  • On 12/20/2016 Amgen announced a quarterly dividend of $1.15 3.15% with an ex dividend date of 2/13/2017 which will be payable on 3/8/2017.
  • On 10/14/2016 Amgen announced a quarterly dividend of $1.00 2.46% with an ex dividend date of 11/14/2016 which will be payable on 12/8/2016.
  • On 7/22/2016 Amgen announced a quarterly dividend of $1.00 2.4% with an ex dividend date of 8/15/2016 which will be payable on 9/8/2016.
  • On 3/2/2016 Amgen announced a quarterly dividend of $1.00 2.74% with an ex dividend date of 5/13/2016 which will be payable on 6/8/2016.
  • On 12/15/2015 Amgen announced a quarterly dividend of $1.00 2.43% with an ex dividend date of 2/11/2016 which will be payable on 3/8/2016.
  • On 10/14/2015 Amgen announced a quarterly dividend of $0.79 2.07% with an ex dividend date of 11/12/2015 which will be payable on 12/7/2015.

Recent Insider Trading Activity For Amgen (NASDAQ:AMGN)
Amgen (NASDAQ:AMGN) has insider ownership of 0.20% and institutional ownership of 79.04%.

  • On 8/2/2016 Annette Louise Such, VP, sold 3,000 with an average share price of $174.59 per share and the total transaction amounting to $523,770.00. View SEC Filing
  • On 5/4/2016 Madhavan Balachandran, EVP, sold 30,000 with an average share price of $154.12 per share and the total transaction amounting to $4,623,600.00. View SEC Filing
  • On 4/29/2016 David Baltimore, Director, sold 3,312 with an average share price of $157.21 per share and the total transaction amounting to $520,679.52. View SEC Filing
  • On 4/29/2016 Sean E Harper, EVP, sold 21,875 with an average share price of $157.99 per share and the total transaction amounting to $3,456,031.25. View SEC Filing
  • On 8/31/2015 Carbonnel Francois De, Director, sold 5,000 with an average share price of $153.84 per share and the total transaction amounting to $769,200.00. View SEC Filing
  • On 8/19/2015 Fred Hassan, Director, bought 3,010 with an average share price of $166.63 per share and the total transaction amounting to $501,556.30. View SEC Filing
  • On 6/2/2015 Cynthia M Patton, SVP, sold 4,530 with an average share price of $157.06 per share and the total transaction amounting to $711,481.80. View SEC Filing

About Amgen (NASDAQ:AMGN)
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Recent Trading Activity for Amgen (NASDAQ:AMGN)
Shares of Amgen closed the previous trading session at 168.61 down -11.50 -6.38% with 23,936,848 shares trading hands.

An ad to help with our costs